Gainers

• Adlai Nortye (NASDAQ:ANL) stock moved upwards by 44.5% to $2.37 during Monday's pre-market session. The market value of their outstanding shares is at $60.5 million.
• Indaptus Therapeutics (NASDAQ:INDP) stock moved upwards by 21.56% to $3.1. The company's market cap stands at $4.4 million.
• BiomX (AMEX:PHGE) stock increased by 18.65% to $2.29. The company's market cap stands at $2.9 million.
• VolitionRX (AMEX:VNRX) shares moved upwards by 9.64% to $0.27. The company's market cap stands at $30.7 million.
• CapsoVision (NASDAQ:CV) stock increased by 9.14% to $14.2. The company's market cap stands at $609.4 million.
• Bluejay Diagnostics (NASDAQ:BJDX) stock rose 9.01% to $0.76. The market value of their outstanding shares is at $1.2 million.

Losers

• IM Cannabis (NASDAQ:IMCC) stock fell 11.2% to $1.27 during Monday's pre-market session. The market value of their outstanding shares is at $7.5 million.
• Rapid Micro Biosystems (NASDAQ:RPID) stock decreased by 9.07% to $2.71. The market value of their outstanding shares is at $132.0 million.
• Xenetic Biosciences (NASDAQ:XBIO) stock fell 7.7% to $1.92. The market value of their outstanding shares is at $4.7 million.
• Bolt Biotherapeutics (NASDAQ:BOLT) stock decreased by 6.95% to $4.96. The market value of their outstanding shares is at $10.2 million.
• IO Biotech (NASDAQ:IOBT) stock decreased by 6.74% to $0.69. The company's market cap stands at $53.1 million.
• Hyperfine (NASDAQ:HYPR) shares decreased by 6.62% to $0.99. The market value of their outstanding shares is at $102.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.